Skip to main content

Table 1 Baseline characteristics, frequency of PJP and prophylaxis prescription

From: Epidemiology, mortality and effectiveness of prophylaxis for Pneumocystis jiroveci pneumonia among rheumatic patients: a territory-wide study

 

Total

PJP

No PJP

P value

Prophylaxis

No prophylaxis

P value

All patients

21,587

48 (0.2%)

21,539 (99.8%)

 

1141 (5.3%)

20,446 (94.7%)

 

 Age

58.1 ± 17.4

58.5 ± 18.4

58.1 ± 17.4

0.85

52.8 ± 17.7

58.3 ± 17.3

< 0.01

 Male

5822 (27.0%)

16 (33.3%)

5806 (27.0%)

0.32

285 (25.0%)

5537 (27.1%)

0.12

 Prophylaxis

1141 (5.3%)

0

1141 (5.3%)

0.10

RA

11,646

13 (0.1%)

11,633 (99.9%)

 

72 (0.6%)

11,574 (99.4%)

 

 Age

63.4 ± 15.8

68.3 ± 17.3

13.4 ± 15.8

0.27

63.7 ± 14.1

63.4 ± 15.8

0.89

 Male

2507 (21.5%)

5 (38.5%)

2502 (21.5%)

0.14

17 (23.6%)

2490 (21.5%)

0.67

 Prophylaxis

72 (0.6%)

0

72 (0.6%)

0.78

SLE

5460

22 (0.4%)

5438 (99.6%)

 

629 (11.5%)

4831 (88.5%)

 

 Age

48.8 ± 16.3

46.8 ± 14.2

48.8 ± 16.4

0.57

46.4 ± 16.6

49.1 ± 16.3

< 0.01

 Male

551 (10.1%)

7 (31.8%)

544 (10.0%)

< 0.01

73 (116%)

478 (9.9%)

0.18

 Prophylaxis

629 (11.5%)

0

629 (11.6%)

0.09

SpA

2918

0

2918 (100.0%)

 

49 (1.7%)

2869 (98.3%)

 

 Age

51.8 ± 16.3

51.8 ± 16.3

60.0 ± 14.6

51.7 ± 16.3

< 0.01

 Male

2229 (76.4%)

2229 (76.4%)

42 (85.7%)

2187 (76.2%)

0.12

 Prophylaxis

49 (1.7%)

49 (1.7%)

IMM

1026

7 (0.7%)

1019 (99.3%)

 

220 (21.4%)

806 (78.6%)

 

 Age

61.8 ± 15.9

66.6 ± 14.6

61.8 ± 15.9

0.43

59.7 ± 13.3

62.4 ± 16.5

0.01

 Male

343 (33.4%)

2 (28.6%)

341 (33.5%)

0.78

78 (35.5%)

265 (32.9%)

0.47

 Prophylaxis

220 (21.4%)

0

220 (21.6%)

0.17

AAV

430

6 (1.4%)

424 (98.6%)

 

135 (31.4%)

295 (68.6%)

 

 Age

65.0 ± 17.8

64.0 ± 18.0

65.0 ± 17.8

0.89

63.7 ± 18.4

65.6 ± 17.5

0.30

 Male

177 (41.2%)

2 (33.3%)

175 (41.3%)

0.70

67 (49.6%)

110 (37.3%)

0.02

 Prophylaxis

135 (31.4%)

0

135 (31.8%)

0.10

SSc

109

2 (1.8%)

107 (98.2%)

 

36 (33.0%)

73 (67.0%)

 

 Age

54.4 ± 15.9

79.0 ± 14.1

54.0 ± 15.6

0.03

52.5 ± 18.5

55.4 ± 14.4

0.37

 Male

15 (13.8%)

0

15 (14.0%)

0.57

8 (22.2%)

7 (9.6%)

0.07

 Prophylaxis

36 (33.0%)

0

36 (33.6%)

0.32

   
  1. PJP Pneumocystis jiroveci pneumonia; SSC systemic sclerosis, AAV ANCA-associated vasculitis; IMM immune-mediated myositis; SLE systemic lupus erythematosus; RA rheumatoid arthritis; SpA spondyloarthritis